XLV vs ARKG

Both XLV and ARKG are ETFs. XLV has a lower 5-year return than ARKG (10.66% vs 33.02%). XLV has a lower expense ratio than ARKG (0.13% vs 0.75%). Below is the comparison between XLV and ARKG.

ARKG XLV
Segment Equity: Global Biotech Equity: U.S. Health Care
Issuer ARK State Street Global Advisors
Net Assets $886.97M $25.75B
Expense Ratio 0.75% 0.13%
Management Style passive (index-based) passive (index-based)
Dividend Yield 2.53% 2.25%
Underlying Index -- S&P Health Care Select Sector Index
YTD Return 128.07% 8.25%
1-Year Return 146.67% 14.12%
3-Year Return 50.31% 12.45%
5-Year Return 33.02% 10.66%
10-Year Return N/A 15.38%

XLV description

The Fund seeks to provide investment results that, before expenses, correspond generally to the price and yield performance of the Health Care Select Sector Index. Under normal market conditions, the fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index.

XLV performance & returns

YTD Return 8.25%
1-Month Return 2.30%
3-Month Return 2.37%
1-Year Return 14.12%
3-Year Return 12.45%
5-Year Return 10.66%
10-Year Return 15.38%
XLV expense ratio is 0.13%.

XLV holdings

Top 10 Holdings (51.64% of Total Assets)

Name Symbol % Assets
Johnson & Johnson JNJ 9.88%
UnitedHealth Group Inc UNH 7.47%
Merck & Co Inc MRK 5.29%
Pfizer Inc PFE 5.14%
Abbott Laboratories ABT 4.86%
Thermo Fisher Scientific Inc TMO 4.40%
AbbVie Inc ABBV 3.90%
Amgen Inc AMGN 3.75%
Medtronic PLC MDT 3.52%
Danaher Corp DHR 3.43%

Other relevant XLV comparisons

You may also want to check out the following XLV comparisons that investors often look for on Finny

Or use Finny Compare Wizard to create a comparison you’d like to see.

ARKG description

The Fund seeks long-term growth of capital. The Fund is an actively-managed exchange-traded fund that will invest under normal circumstances primarily in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary.

ARKG performance & returns

YTD Return 128.07%
1-Month Return 7.12%
3-Month Return 22.40%
1-Year Return 146.67%
3-Year Return 50.31%
5-Year Return 33.02%
10-Year Return N/A
ARKG expense ratio is 0.75%.

ARKG holdings

Top 10 Holdings (53.10% of Total Assets)

Name Symbol % Assets
Invitae Corp NVTA 12.01%
CRISPR Therapeutics AG CRSP 8.05%
Pacific Biosciences of California Inc PACB 5.64%
Twist Bioscience Corp TWST 4.71%
Arcturus Therapeutics Holdings Inc ARCT 4.71%
Compugen Ltd CGEN 4.42%
Seres Therapeutics Inc MCRB 3.68%
Iovance Biotherapeutics Inc IOVA 3.48%
Teladoc Health Inc TDOC 3.26%
Personalis Inc PSNL 3.14%

Other relevant ARKG comparisons

You may also want to check out the following ARKG comparisons that investors often look for on Finny

Or use Finny Compare Wizard to create a comparison you’d like to see.

You can check out all comparisons Finny users have looked for here. Feel free to the browse the list and view the comparisons that are of an interest to you.

7-day free trial: Get unlimited comparisons, and stock, ETF and mutual fund analyses for just $15 a month, without ads. Start a free trial. Go ad free!

Follow Us